4//SEC Filing
Sabba Stephen L 4
Accession 0001104659-25-035352
CIK 0000886163other
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 9:34 AM ET
Size
8.4 KB
Accession
0001104659-25-035352
Insider Transaction Report
Form 4
Sabba Stephen L
Director
Transactions
- Exercise/Conversion
Common Stock
2025-04-01$52.30/sh+2,406$125,834→ 32,584 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-04-01−2,406→ 0 totalExercise: $52.30Exp: 2025-04-24→ Common Stock (2,406 underlying)
Footnotes (2)
- [F1]These securities, as represented in Column 5, includes the grant of 1,252 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 14, 2024, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 25 June 2024, which was filed to reflect the 2024 Meeting grant.
- [F2]These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001442372
Filing Metadata
- Form type
- 4
- Filed
- Apr 15, 8:00 PM ET
- Accepted
- Apr 16, 9:34 AM ET
- Size
- 8.4 KB